Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT538 in AML and Multiple Myeloma
NCT04614636Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Oct 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT538 in acute myeloid leukemia (AML) and multiple myeloma (MM) (3 arms), sponsored by Fate Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities and Nature of Dose-Limiting Toxicities. Started Oct 2020; status: terminated.
02
Drugs
FT538
03
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04614636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614636.